Silencing Investor Concerns? Alnylam Achieves RNAi Milestone

News   Aug 01, 2012

 
Silencing Investor Concerns? Alnylam Achieves RNAi Milestone
 
 
 

RELATED ARTICLES

BC Platforms Announces Collaborations in Multiple Sclerosis Research

News

Company's technology and research platforms used to better understand genetic basis of MS.

READ MORE

Pathway in Neurons may Contribute to Neurodegenerative Disease

News

Pathway has received attention as potential drug target.

READ MORE

Biomedical Catalyst Award Goes To BioMoti, Pharmidex and Queen Mary University of London

News

The grant was awarded under the Biomedical Catalyst funding competition to support preclinical studies of new therapeutic approaches for hard-to-treat tumours including advanced ovarian, triple negative breast and pancreatic cancers.

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Cell Science Genomics Research

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE